BioCentury | Nov 21, 2020
Product Development

Could an approval of Biogen’s Alzheimer’s therapy still be an option?

...of brain swelling, known as amyloid-related imaging abnormalities (ARIA), ...
...only the patients who did not develop ARIA. None...
...It could be helpful for thinking about ARIA...
BioCentury | Mar 14, 2020
Politics, Policy & Law

Patient access to new Alzheimer’s drugs will depend on diagnostic innovation and payment reform

If Biogen’s Alzheimer’s disease therapy aducanumab gets approved this year, it will set off a payment time bomb given the huge patient population, and the fact it almost exclusively falls in the Medicare age group....
BioCentury | Dec 6, 2019
Clinical News

Biogen Alzheimer’s data won’t sway believers or doubters either way

...same dose or titrate up to their original dose if they experienced amyloid-related imaging abnormalities (ARIA...
...made nine months before the 10 mg/kg dosing amendment. “They may have also benefited from ARIA...
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

...pathway iterates based on actual patient feedback and the actual objective outcomes from the EMR,” Aria...
...creates a continuous cycle of data collection that loops back and into the care pathway.” Aria...
BioCentury | Nov 9, 2018
Clinical News

Biogen's aducanumab shows continued improvements through 48 weeks in Phase Ib extension for Alzheimer’s

...8.22, 12.62 and 4.82 points, respectively. There were no new cases of amyloid-related imaging abnormalities-edema (ARIA-E...
BioCentury | Oct 26, 2018
Clinical News

Data raise possibility BAN2401 primarily benefits Alzheimer’s subgroup

...this dose because they have been shown to be more susceptible to amyloid-related imaging abnormalities-edema (ARIA-E...
BioCentury | Oct 25, 2018
Clinical News

Data raise possibility BAN2401 primarily benefits Alzheimer’s subgroup

...this dose because they have been shown to be more susceptible to amyloid-related imaging abnormalities-edema (ARIA-E...
BioCentury | Oct 28, 2017
Strategy

Biogen doubles down

...reduced in a titration arm intended to help reduce the rates of amyloid-related imaging abnormalities (ARIA...
...carriers of the apolipoprotein E (APOE) epsilon 4 (APOE4) allele, who are more susceptible to ARIA...
BioCentury | Feb 17, 2017
Company News

Incyte sales and marketing update

...through the country’s Cancer Drugs Fund (CDF). Incyte granted European rights to Ariad Pharmaceuticals Inc. (NASDAQ:ARIA...
BioCentury | Feb 8, 2017
Clinical News

Brigatinib regulatory update

...close at the end of this month (see BioCentury, Jan. 16 ). Ariad Pharmaceuticals Inc. (NASDAQ:ARIA...
Items per page:
1 - 10 of 666